Skip to main content
Premium Trial:

Request an Annual Quote

Quest Makes Equity Investment in Correlogic

NEW YORK, June 9 (GenomeWeb News) - Quest Diagnostics has made an equity investment in Correlogic Systems, the companies said today.


The companies declined to disclose the amount of funding.


Quest retains an option to commercialize specific Correlogic diagnostics for particular disease states, the companies said. The company has also licensed Correlogic's OvaCheck for commercialization, the companies said.


OvaCheck was the subject of a February letter sent to Correlogic by Steve Gutman, director of the US Food and Drug Administration's Office of In Vitro Diagnostic Device Evaluation and Safety notifying the company that the diagnostic may be subject to the agency's premarket review requirements.


OvaCheck is now in validation testing, Correlogic said.


Correlogic is also developing a prostate cancer diagnostic with the UniformedServicesUniversityof the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine based on the company's protein pattern-recognition approach, the company said in May.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.